Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.59 EUR | -1.52% | -5.82% | +7.92% |
Apr. 05 | Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors | CI |
Mar. 22 | Finland's Bioretec Gets US Patent Allowance for Magnesium Alloy Composition | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.92% | 57.31M | - | ||
+72.92% | 12.36B | B- | ||
-19.68% | 7.83B | C+ | ||
+16.20% | 7.21B | C- | ||
+4.77% | 5.97B | B | ||
+7.49% | 5.14B | D+ | ||
+23.97% | 4.43B | - | ||
-18.81% | 3.9B | B- | ||
-41.54% | 2.2B | C | ||
+1.61% | 2.02B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BRETEC Stock
- Ratings Bioretec Oy